Clinical trial XL184-311
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy
| Cancers | |
|---|---|
| Organ | Thyroïd |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Exelixis |
| EudraCT Identifier | 2018-001771-21 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03690388 |
| Inclusion criteria | RECIST 1.1 |
| Last update |